Thiotepa Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 15 mg, 100 mg
Reference Brands: Thioplex (USA/EU) , Tepylute (USA)
Category:
Oncology Cancer Care
Thiotepa is available in Injection
and strengths such as 15 mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Thiotepa is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Thiotepa can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Thiotepa is a chemotherapy medication classified as an alkylating agent, sold under the brand name Tepadina and other regional brands. It works by directly damaging the DNA of rapidly dividing cells, preventing cell replication and ultimately leading to cell death. This mechanism makes thiotepa effective against a variety of cancers, including breast cancer, ovarian cancer, bladder cancer, and hematologic malignancies.
As an alkylating agent, thiotepa interferes with the normal function of cancer cell DNA, disrupting their ability to grow and multiply. It is used in clinical settings for systemic therapy as well as in conditioning regimens prior to bone marrow or stem cell transplantation. Thiotepa’s targeted cytotoxic action provides an important option for treating malignancies that are responsive to DNA-alkylating chemotherapy, and its use is carefully monitored due to potential side effects associated with chemotherapy agents.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing